Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01913366
Other study ID # R01AG043584-01A1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 2013
Est. completion date March 31, 2019

Study information

Verified date July 2019
Source University of California, San Francisco
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Dr. Brooke Hollister, Ph.D. from the department of Social and Behavioral Sciences at the University of California, San Francisco is conducting a study comparing two types of interventions for treating depression in rural older adults.


Description:

If you are eligible to participate in the study after completing the screening assessment, and if you choose to continue on, we will randomize you (like a flip of a coin) to receive either 12 weeks of case management combined with problem solving therapy (CM-PST) with a social worker or 12 weeks of self-guided problem solving therapy (SG-PST) with support from a senior peer counselor.

As part of your participation in the study you will participate in three 1.5 hour assessment interviews of psychological and neuropsychological functioning (similar to your screening assessment) prior to your first week of treatment (baseline), two weeks after your final session (week 14), and three months after your final session (week 24). Additionally, you will participate in three shorter assessment interviews of psychological functioning, which will be conducted at weeks 3 and 6. These assessments will take approximately 30-45 minutes.


Recruitment information / eligibility

Status Completed
Enrollment 105
Est. completion date March 31, 2019
Est. primary completion date August 2018
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria:

- Residence in rural Tuolumne, Calaveras, San Joaquin or Stanislaus Counties;

- Diagnosis: Major depression, unipolar (by SCID ascertained DSM-IV criteria);

- Severity of depression: A PHQ-9>10 or a 24-Item HDRS>19;

- Need for social services: CANE score> 2, i.e. at least one unmet need;

Exclusion Criteria:

- Psychotic depression by SCID-IV, i.e., presence of delusions;

- High suicide risk, i.e. intent or plan to attempt suicide in near future;

- Presence of any Axis I psychiatric disorder or substance abuse other than unipolar major depression;

- Axis II diagnosis of antisocial personality (by SCID-P and DSM-IV);

- History of psychiatric disorders other than unipolar major depression or generalized anxiety disorder (including bipolar disorder, hypomania, and dysthymia);

- Dementia: MMSE below 24 or clinical diagnosis of dementia by DSM-IV;

- Acute/severe medical illness (delirium, metastatic cancer, de-compensated cardiac, liver or kidney failure, stroke or myocardial infarction) 3 months prior to entry; or use of drugs causing depression, (steroids, reserpine, alphamethyl-dopa, tamoxiphen, vincristine);

- Inability to perform any of the ADLs (MAI: ADL subscale) even with assistance (walking with a cane is not an exclusion criterion)

- Inability to speak English;

- Aphasia interfering with communication;

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
CM-PST

SG-PST


Locations

Country Name City State
United States Catholic Charities Motherlode Office- Sonora Sonora California

Sponsors (1)

Lead Sponsor Collaborator
University of California, San Francisco

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Hamilton Rating Scale for Depression (HRSD) A multiple item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery. Baseline
Primary Hamilton Rating Scale for Depression (HRSD) A multiple item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery. Week 3
Primary Hamilton Rating Scale for Depression (HRSD) A multiple item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery. Week 6
Primary Hamilton Rating Scale for Depression (HRSD) A multiple item questionnaire used to provide an indication of depression, and as a guide to evaluate recovery. Week 12
Primary WHO Disability Assessment Schedule 2.0 (WHODAS-II) Generic assessment instrument for health and disability Week 0
Primary WHO Disability Assessment Schedule 2.0 (WHODAS-II) Generic assessment instrument for health and disability Week 3
Primary WHO Disability Assessment Schedule 2.0 (WHODAS-II) Generic assessment instrument for health and disability Week 6
Primary WHO Disability Assessment Schedule 2.0 (WHODAS-II) Generic assessment instrument for health and disability Week 12
See also
  Status Clinical Trial Phase
Completed NCT04482296 - Effect of Zinc Supplementation on Depression in SSRI-treated Major Depressive Disorder Patients N/A
Recruiting NCT04071886 - Effect of Short-Term Mindfulness-Based Training For Major Depression Disorder: An Eye-Tracking Study N/A
Completed NCT04076644 - Maintenance Transcranial Magnetic Stimulation in Major Depressive Disorder N/A
Completed NCT05528315 - SAD/MAD of ABX-002-1902 Investigating the Safety, Pharmacokinetics/Pharmacodynamics of in Healthy Subjects Phase 1
Recruiting NCT05437588 - Neural-Derived Plasma Exosomal MicroRNAs As Promising Novel Biomarkers for Suicidality and Treatment Outcome in Adolescents N/A
Recruiting NCT06095778 - rTMS Therapy for Treatment-Resistant Depression With Different Targets Guided by pBFS N/A
Active, not recruiting NCT05657691 - Xanamem® in Adults With Major Depressive Disorder and Impaired Cognition (XanaCIDD) Phase 2
Completed NCT02013609 - Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Active Adults, 18 to 35 Years Old, With Major Depressive Disorder Who Are in a School or Work Environment Phase 3
Completed NCT02339285 - Transcranial Alternating Current Stimulation for Major Depressive Disorder N/A
Recruiting NCT03971305 - A Prospective Multicenters Clinical Cohort Study of Stratified Treatment of Chinese Children With Systemic ALK(+) ALCL
Recruiting NCT05169346 - Neurofeedback to Treat Depression N/A
Completed NCT01344733 - A Non Interventional Study to Investigating the Ratio of Mis-diagnosed Bipolar Symptoms in Patient With Major Depressive Disorder (MDD) N/A
Completed NCT04268316 - Virtual Reality Behavioral Activation: An Intervention for Major Depressive Disorder N/A
Active, not recruiting NCT01557946 - Glutamatergic and GABAergic Mediators of Antidepressant Response in Major Depression Phase 2
Recruiting NCT01501812 - Evaluation of Generalization Paradigm Patterns Among Different Psychiatric Disorders N/A
Completed NCT04880460 - Effect of Magnesium Supplementation in Selective Serotonin Reuptake Inhibitors Treated Major Depressive Disorder Patients Phase 2
Completed NCT04226352 - Three Dosing Regimens of Dextromethorphan (DXM) Reportedly Used in Major Depressive Disorder Phase 1
Recruiting NCT03754712 - Effect of Vitamin D Administration Along With SSRIs in Patients With Major Depressive Disorder N/A
Recruiting NCT02669030 - A Six Week, Randomized, Double-Blind Placebo-Controlled, Suvorexant Augmentation Study of Antidepressant Treatment of Major Depressive Disorder With Residual Insomnia Phase 4
Completed NCT03994081 - Mechanism of Action of tACS for the Treatment of MDD N/A